Operating expenses for the prior year periods included
technology access fees to the University of California triggered by
the Organon milestone and significant non-cash stock compensation
charges. Neither of these non-cash amounts had any impact on
Cortex's working capital or its liquidity.

mixing psychiatric

For more information, call: Damian McIntosh or Dian Griesel, Ph.20 per share for
the corresponding prior year period.com

com .

blog psychiatry

V.globalprblogweek.

For media inquiries, please contact John Cass at 781.

psychiatry psychotherapy

The report covering
the transition period will be filed in a Form 10-K.
Other income for the current year periods included $499,000
related to the change in estimated value of warrants issued in
Cortex 's December 2004 private placement. Cortex has alliances with N.0, will be held September 19-23, 2005 .

The planning of Global PR Blog Week was done mostly on the internet, by
using a public Yahoo! Groups discussions list, and the New PR Wiki, a
collaboration space for professionals interested in the practice of public
relations, hosted at http://www.

psychotherapy headlines

Business Editors/Health/Medical Writers

IRVINE, Calif. The discussion will be followed by a question
and answer session.
at The Investor Relations Group, Inc. These imbalances may be improved by using the
AMPAKINE technology . Excluding these amounts from the prior year periods
highlights the increased research and development expenses incurred
during the six months ended December 31, 2004. As discussed in the Company's Securities
and Exchange Commission filings, the Company's proposed products will
require additional research , lengthy and costly clinical testing and
regulatory approval.467.

nearly findings

For both the three months and six months ended December 31, 2004,
decreased revenues primarily resulted from the $2,000,000 milestone
payment from Organon in late December 2003. These imbalances may be improved by using the
AMPAKINE technology. The
success of such activities depends on a number of factors, including
the risks that the Company's proposed products may at any time be
found to be unsafe or ineffective for any or all of their proposed
indications; that competitors may challenge or design around the
Company 's patents or develop competing technologies; and that clinical
studies may at any point be suspended or take substantially longer
than anticipated to complete.

About Global PR Blog Week
The Global PR Blog Week 2.

entries szasz

09 per share for the quarter ended December 31, 2004 compared
with net income of $512,000, or $0.
In November 2004 the Company's Audit Committee, under authority
from the Board of Directors, approved a change in the Company's fiscal
year from June 30 to December 31 .

entries forensic

About Cortex Pharmaceuticals, Inc.

Cortex, located in Irvine, California, is a neuroscience company
focused on novel drug therapies for neurological and psychiatric
disorders. For the six months ended
December 31, 2003, the related change for warrants issued in Cortex's
August 2003 private placement resulted in other expenses of
$3,499,000. Organon for the
treatment of schizophrenia and depression and with Les Laboratoires
Servier for the development of AMPAKINE compounds to treat the
neurodegenerative effects associated with aging and disease, including
Mild Cognitive Impairment , Alzheimer's disease and anxiety disorders.
Condensed Statements of Operations
(in thousands, except per share data)

Transitional
Three months ended Six months ended
December 31, December 31,
2004 2003 2004 2003
(Unaudited) (Unaudited ) (Unaudited)

Revenues $ 721 $ 3,256 $ 1,896 $ 4,594
Operating expenses:
Research and development 2,885 1,837 4,926 2,870
General and administrative 866 695 1,530 1,155
Non-cash stock
compensation charges 102 566 152 889
Total operating expenses 3,853 3,098 6,608 4,914
Income (loss) from
operations (3,132) 158 (4,712 ) (320)
Interest income, net 98 9 167 13
Change in fair value of
common stock warrants 499 345 499 (3,499)
Net income (loss ) $ (2,535) $ 512 $ (4,046) $ (3,806)

Income (loss) per share:
Basic and diluted $ (0.

psychiatry explained

02 per share for the corresponding
prior year period.14) $ (0.globalprblogweek .

findings weblogs

The Company is pioneering a class of proprietary
pharmaceuticals called AMPAKINE compounds, which act to increase the
strength of signals at connections between brain cells.

weblogs neuroscience

----Cortex
Pharmaceuticals , Inc. Many psychiatric diseases, including
schizophrenia, occur as a result of imbalances in the brain's
neurotransmitter system.cortexpharm.

Forward-Looking Statement

Note -- This press release contains forward-looking statements
concerning the Company's research and development activities. AMPAKINE compounds are investigational drugs and
have not been approved for the treatment of any disease.09) $ 0.
Condensed Balance Sheets
(in thousands)

December 31, June 30 ,
2004 2004
Assets:
Cash and cash equivalents $ 9,157 $ 9,977
Marketable securities 18,838 12,211
Accounts receivable 42 133
Other current assets 318 268

28,355 22,589

Furniture, equipment and
leasehold improvements, net 388 269
Capitalized financing costs 1,136 --
Other 33 33
Total assets $ 29,912 $ 22,891

Liabilities and Stockholders'
Equity:
Accounts payable and accrued
expenses $ 1,907 $ 1,815
Unearned revenue -- current 377 206
Unearned revenue, other
non-current 23 381
Common stock warrants 3,958 --
Stockholders ' equity 23,647 20,489
Total liabilities and
stockholders ' equity $ 29,912 $ 22,891


More information at www.com.0, please
visit http://www.

psychology mainstream

Cortex Reports Operating Results for December 31 2004

Pharmaceutical Writers/Business Editors/Financial Editors

IRVINE, Calif.

For psychology, cognitive science, and research-related weblogs and blogs written primarily for or by professionals in psychology .

psychiatric psychotherapy

Cortex to Host Conference Call to Discuss Results for the Six-Months Ended December 31 2004

Cortex Pharmaceuticals, Inc.

perception blogs

20)

Shares used in computing
per share amounts
Basic 28,355 20,640 28,355 19,480
Diluted 28,355 23,909 28,355 19,480


Cortex Pharmaceuticals, Inc.

hacks mixing

Effective November 4, 2004, the Company's Audit Committee under
authority from the Board of Directors approved a change in the
Company's fiscal year from June 30 to December 31. 210, or
via email at john@backbonemedia .

szasz forensic

(AMEX: COR) will host a conference call on
Wednesday, March 23, 2005 at 11:00 AM Pacific Time (2:00 PM Eastern
Time) to discuss the Company's financials for the six-month
transitional period ended December 31, 2004, to update shareholders on
the development of the CX717 compound, and to discuss other
AMPAKINE(R) programs. (AMEX: COR) reported a net loss of $2,535,000,
or $0. Many psychiatric diseases, including
schizophrenia, occur as a result of imbalances in the brain's
neurotransmitter system.02 $ (0.cortexpharm.
During this year's five-day forum, participants from Argentina , Canada,
Denmark, France, Germany, Ireland, Italy, Netherlands, Romania, Spain, United
Kingdom and the United States will publish more than 70 case studies, articles
and interviews covering the latest breakthroughs in online technology
including:

* Challenges of corporate blogging
* Blog relations
* Education for the New PR
* Types of corporate blogs
* Tools, trends, and practices (including blog monitoring, podcasting,
wikis, and online media rooms)
* Customer generated marketing
* Transparency + ethics
* Mainstream media and citizen journalism

For a complete list of participants and conference schedule visit:
http://www.

hacks findings

S.D. Organon for the
treatment of schizophrenia and depression and with Les Laboratoires
Servier for the development of AMPAKINE compounds to treat the
neurodegenerative effects associated with aging and disease, including
Mild Cognitive Impairment, Alzheimer's disease and anxiety disorders .
With its December 2004 private placement of common stock and
warrants, Cortex further improved its balance sheet. The net proceeds
from the financing approximated $10,400,000 and allow Cortex to
advance its development plans for CX717, as well as other AMPAKINE
compounds.

Cortex , located in Irvine, California, is a neuroscience company
focused on novel drug therapies for neurological and psychiatric
disorders.4050 ext.

psychotherapy mixing

and Canada: 1-800-500-0177

International: 1-719-457-2679

A replay will be available for 45 days after the call by dialing
1-888-203-1112 (US and Canada ) or 1-719-457-0820 (International) and
entering access code 2436331 when prompted.

PR Professionals and Blogging Experts Team to Participate in the Second Annual Global PR Blog Week

For more information about the Global PR Blog Week 2.com.com.

blog findings

The loss of
these connections is thought to be responsible for memory and behavior
problems in Alzheimer's disease.com/

Cortex Pharmaceuticals, Inc.
The forum will bring more than 50 influential PR practitioners and
bloggers in an online environment to discuss how public relations and business
communications are changed by new communications technologies including,
weblogs, podcasting, RSS, and wikis.

The event is free and open to everybody -- for asking questions, making
comments and participating in the discussion through the event's weblog.0 is an online event that will engage public
relations , marketing and business professionals from around the globe in a
discussion about how new communications technologies are changing public
relations and business communication.

psychiatry szasz

Operating expenses for both the three months and six months ended
December 31, 2004 reflect increased development expenses for the
AMPAKINE compound CX717, which is currently in Phase II clinical
testing. Cortex's cash and marketable securities increased to nearly
$28,000,000 as of December 31, 2004.thenewpr.com or contact Jeremy Pepper at 480.

explained blog

For the transitional six-month period ended
December 31, 2004, Cortex reported a net loss of $4,046,000, or $0.

entries psychiatry

Participants are asked to call the following numbers 5-10 minutes
prior to the starting time:

From the U. Cortex has alliances with N. The Company is pioneering a class of proprietary
pharmaceuticals called AMPAKINE compounds, which act to increase the
strength of signals at connections between brain cells. The loss of
these connections is thought to be responsible for memory and behavior
problems in Alzheimer's disease.4457,
or via email at jeremy@poppr.

sensation blogs

Phone: 212-825-3210.14
per share compared to a net loss of $3,806,000, or $0. A report covering the transitional
period will be filed on a Form 10-K.V. Participants Will Discuss How PR Should Change in the New Era of Blogging

NEW YORK, The second annual PR blogging summit ,
Global PR Blog Week 2.899.

implications perception

----Cortex
Pharmaceuticals, Inc.

neuroscience forensic

(http://www. The event is scheduled for September
19 - 23, 2005.

psychotherapy mixing

---

- - kjjkjk

Loading...

(Note: These pages use the Atlas Content Safeguard System (ACSS) and require that Javascript is enabled for viewing.)